Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. - Wikidata - wikimedia - TriplyDB

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.

http://www.wikidata.org/entity/Q34352100

about

Recent advances in the management of mucormycosis: from bench to bedside Advances in the treatment of invasive neonatal candidiasis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Echinocandins: the newest class of antifungals.Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Management of neonatal candidiasis. Neonatal Candidiasis Study Group Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.Pharmacokinetics of antifungal agents in children.Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.A review of clinical experience with newer antifungals in children Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Anidulafungin: a new echinocandin for candidal infections.The echinocandins.Anidulafungin--state of affairs from a clinical perspective.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Clinical pharmacology of antifungal agents in pediatric patients.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Anidulafungin: a novel echinocandin for candida infections.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.Economic return of clinical trials performed under the pediatric exclusivity program.Pediatric antifungal agents.Invasive fungal infections in the ICU.A clinical review of echinocandins in pediatric patients.

P2860

Q24642450-E283BEA8-6F79-46B2-991C-8CF8379A56D2 Q27022585-2143B192-9E9D-4515-832F-3F9F2A22FDF0 Q27025299-9222ED94-C846-41D8-9028-F1919CEEC9A2 Q33490772-9DAF482C-5BB7-4150-9A23-AFBA2B57797E Q33650105-C1144C8F-E5D8-4C86-BE3E-D7892A53A2BF Q33688646-EB3A90C3-7331-4F94-811E-3A0B560A09BC Q33827819-B9169855-E045-4A2D-8CC5-D6F4BE501452 Q34019188-86D29CF8-34A0-452F-9B4F-FC907AD7F9D8 Q34151170-723EAA8D-64E2-46A0-A31D-2E952B0435FD Q34212799-CA857738-A51E-4932-8107-16DE88368D75 Q34505582-104D3D46-B71A-411D-8BA1-07690326605B Q34522746-5367BB28-4C5C-44FC-8D27-7B4360DF81BA Q34532546-00C45C7C-0374-4707-A1CE-A924A69A8587 Q34680771-8D4C4FC6-85B3-4F22-9A39-E879DE2B2F74 Q35071572-708A8BEF-C0A9-425A-A94D-4BCB29D600D9 Q35105787-88DEFDB6-2086-49DB-86F7-1D773CD80581 Q35140020-5BFDD12A-29B6-46F5-9612-F33305731281 Q35689202-1EA3DB02-4C22-43A1-B041-A5696987D906 Q35959484-8B545EB3-F980-4394-952D-7AE7F66C871E Q35959489-ED46D027-A950-4FCF-A671-30F175B183E5 Q36094957-1949BB04-1C04-4696-911B-C9A7B59EAFB0 Q36163345-46071CDD-67A9-4CF5-8B26-FF0EAE7AB8FE Q36276191-D7F04758-3A27-44A4-BBE1-D7CE1C854493 Q36290698-F7B85AB1-DE87-4078-9D74-59A4B5257CE4 Q36505401-5EA69D29-58CC-4D6F-BA3B-F52755EBFC05 Q36624970-11576DA1-AEF3-4B4C-897E-5A73A77D0D54 Q36626518-FC643733-B3ED-4BF3-A7F4-B2424E12A865 Q36723788-011C2A06-7F2A-4386-83E0-C4BEF9E9FA41 Q36742397-B985EBE0-BD71-4FE0-BB31-7C998E10D9DB Q36774257-D9FA8F34-1325-4334-B843-278F9130989D Q36822025-28D117D8-53AE-4C4B-B7F4-6BC5ABDC0C73 Q36948094-7190228A-CD8A-48D2-B3BF-7F536FA73085 Q36968140-E48F25E1-1F3C-40AE-AC16-336BC84A5B7D Q37157893-B2ACB84B-78EB-4A22-B462-E8097ED59209 Q37345790-DAA1154E-A1AC-4CE3-A4F3-CB2ECF1E190F Q37359613-6062C240-EA13-47A0-B209-4DC147F5B642 Q37412752-4B39619A-5792-48A9-90AC-BD6976ECAE33 Q37594515-8B3307E6-0D33-4FB5-BF8C-C6B7E307D911 Q37643057-299D1D91-D35B-421A-BB9E-4E44A8ABE965 Q37653647-FBE0EED9-A656-41B6-975B-8CEA169DDEBA

P2860

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.

http://www.wikidata.org/entity/Q34352100

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Safety and pharmacokinetics of ...... or invasive fungal infections.

@ast

Safety and pharmacokinetics of ...... or invasive fungal infections.

@en

Safety and pharmacokinetics of ...... or invasive fungal infections.

@nl

type

label

Safety and pharmacokinetics of ...... or invasive fungal infections.

@ast

Safety and pharmacokinetics of ...... or invasive fungal infections.

@en

Safety and pharmacokinetics of ...... or invasive fungal infections.

@nl

prefLabel

Safety and pharmacokinetics of ...... or invasive fungal infections.

@ast

Safety and pharmacokinetics of ...... or invasive fungal infections.

@en

Safety and pharmacokinetics of ...... or invasive fungal infections.

@nl

P1433

Q34352100-8BAA9A04-39B1-4285-B505-6DF7F3B61F58

P1476

Q34352100-3247D72D-9B7C-4F8F-9E2C-A9D071690926

P2093

Q34352100-0D3AAE12-C920-411C-8F94-5BCF69B83FB1

Q34352100-259B6BA2-1B42-4BBF-BD65-1E4701F42775

Q34352100-270BCC87-70C6-44FA-9675-377C3C6622A6

Q34352100-2EE6B28F-B9A9-43A5-9206-844518AEF15D

Q34352100-3AE9B4A1-9B57-4F39-B621-D2ABEA4979F0

Q34352100-48AD1100-B08F-4F3F-8CBE-5C8F2E806B8F

Q34352100-632EA5C1-4B4A-4B12-8AC1-7AC7A734FE8D

Q34352100-C19ECED4-6DC6-4C3E-8BDC-A15DA1298D45

Q34352100-F59221D9-B9CF-4E76-84C2-5F8F16E6EAEA

P2860

Q34352100-104BA5DB-EA69-4568-8A0A-AD4378E19431

Q34352100-2E227985-CFD5-4FBE-9C5A-5EDBCFB44F38

Q34352100-391FFA52-0EE9-4C4B-BA93-7F21841D52E5

Q34352100-4BC08D4F-D032-43B1-BAAA-D29808DF2CA6

Q34352100-505169F0-CE07-4FE2-80C7-AA6700933C67

Q34352100-75BFBFAB-2D51-429E-BB2E-36566445301A

Q34352100-84457590-8387-4A44-BF08-0AF8780A255B

Q34352100-8F521D56-4E73-4880-AEF2-6EFD808FD36C

Q34352100-AF441AB7-F253-4C10-B3AC-8B24709C0B0B

Q34352100-B0C91E8B-8559-4F4B-BC05-08EFA6238674

P304

Q34352100-082DE28D-5F59-4F88-819E-BC587FABE6EF

P31

Q34352100-0E94840F-381D-4133-A757-DE392CC29785

P356

Q34352100-058BB50D-E15C-44B2-9097-D570215285F6

P407

Q34352100-27778CDB-894B-4FD3-985A-33CFD1F8DD45

P433

Q34352100-944962C6-CC71-4A74-9643-81C62BF69AF3

P478

Q34352100-2654E057-CEF7-47D3-9FFF-FA0640798249

P50

Q34352100-E8BB8C95-9165-4339-ABE3-85027DF41807

P577

Q34352100-6134C861-81BA-484F-9959-BDDC609D9FFE

P698

Q34352100-41557C6C-101E-4F2E-876B-76B6075D168B

P932

Q34352100-C64FCD67-E7D3-44CD-98C5-B47B2CAC0124

P356

AAC.50.2.632-638.2006

P1433

Antimicrobial Agents and Chemotherapy

P1476

Safety and pharmacokinetics of ...... or invasive fungal infections.

@en

P2093

Corina E Gonzalez

http://www.w3.org/2001/XMLSchema#string

Daniel K Benjamin

http://www.w3.org/2001/XMLSchema#string

James A Dowell

http://www.w3.org/2001/XMLSchema#string

Jennifer Schranz

http://www.w3.org/2001/XMLSchema#string

Kay Clark

http://www.w3.org/2001/XMLSchema#string

Maureen M Roden

http://www.w3.org/2001/XMLSchema#string

Rahki Kilaru

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

Timothy Driscoll

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

Evaluation of endpoints for antifungal susceptibility determinations with LY303366.

Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

P304

632-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.50.2.632-638.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16436720

http://www.w3.org/2001/XMLSchema#string

P932

1366891

http://www.w3.org/2001/XMLSchema#string